Immunovant, Inc. (IMVT) - FY2026 Investor Guide

Thinking about investing in Immunovant? Here is a plain-English breakdown of their annual report for the year ending March 31, 2026.

Immunovant is a clinical-stage biotech company (ticker: IMVT) with 315 employees (85% in R&D) and 205.3 million shares.

1. What does Immunovant do?

Immunovant has no approved drugs and zero revenue. It focuses entirely on developing IMVT-1402, a drug candidate for rare, IgG-mediated autoimmune diseases.

• How it works: The drug blocks a protein called FcRn. This stops the body from recycling IgG antibodies, helping to clear these harmful antibodies quickly.
• The Opportunity: Over 4 million patients in the U.S. and Europe suffer from these diseases.
• The Goal: A simple, self-used injection pen (the YpsoMate autoinjector). It aims to cut harmful IgG antibodies by about 80% without raising bad cholesterol.

2. The Big Pivot: All Eggs in One Basket

In April 2026, Immunovant's first drug, batoclimab, failed two Phase 3 trials for Thyroid Eye Disease. Management stopped its development to focus solely on IMVT-1402.

This pivot cost a hefty $39.0 million in contract cancellation fees. The company still faces potential exit penalties and disputes with former research partners.

3. The Good News: Monopoly Shields

To block cheap generic copycats, Immunovant relies on three shields:

• Patents: Key patents protect IMVT-1402's recipe until 2043, with potential extensions to 2046.
• 12-Year Shield: U.S. law blocks cheap copycat drugs for 12 years after FDA approval.
• Rare Disease Shield: A July 2025 law (OBBBA) protects rare-disease drugs from government Medicare price negotiations, preserving pricing power.

4. Key Risks: What Could Go Wrong?

• Roivant's Control: Parent company Roivant owns 55.2% of the voting power. This lets Immunovant bypass key investor protection rules, like having independent directors oversee executive pay. Removing a director requires a massive 66.7% supermajority vote, leaving minority shareholders with little say.
• Partner Disputes: Immunovant licensed IMVT-1402 from HanAll Biopharma. If they breach the contract, they risk losing the drug rights. They owe HanAll up to $420 million in milestones plus royalties. Returning the failed batoclimab drug could spark costly legal battles.
• Tax Risks: Operating in the U.S., UK, Switzerland, and Bermuda invites tax audits. New global minimum tax rules could also raise costs.
• Outsourced Manufacturing: Immunovant owns no factories or labs. It relies entirely on third parties to make its drugs. Any disruptions will halt clinical trials.
• More Shares Issued: With zero revenue, the company must sell more shares to fund operations. This reduces your ownership percentage and voting power.

5. The Financials: High Burn, Zero Revenue

• Revenue: $0.
• Annual Loss: $505.6 million (up 22.2% from last year's $413.8 million loss).
• Where the money goes: Operating costs rose 21.6% to $532.9 million. R&D spending jumped 26.5% to $456.7 million due to trials, hiring, and the $39.0 million cancellation fee. Overhead stayed flat at $76.2 million.
• Interest Income: The company earned $25.3 million by investing its cash.
• The Cash Pile: $902.1 million (up from $714.0 million).
• How they got cash: They raised $543.7 million in December 2025 by selling 26.2 million new shares, reducing existing investor ownership. Roivant bought 16.6 million of these shares. They can sell up to $150 million more in shares if needed.
• Cash Runway: The company burned $407.3 million running its business. Its cash pile should last about 2.2 years, funding operations into mid-2028.
• Lifetime Losses: $1.75 billion since starting.
• Dividends: $0. The company plans to reinvest all future earnings.

6. Future Outlook: What to Watch

Immunovant has 6 active clinical programs. Watch for these key trial results:

• Second Half of 2026: Watch for results in Cutaneous Lupus Erythematosus (CLE) and Rheumatoid Arthritis (D2T RA). Early arthritis data showed 72.7% of patients improved by 20% or more.
• Calendar Year 2027: Watch for results in Graves' Disease and Myasthenia Gravis.
• Calendar Year 2028: Watch for Phase 3 results in CIDP (a nerve disease) and Sjögren's Disease results.

7. The Bottom Line: Is Immunovant Right for You?

Investing in Immunovant is a high-risk, high-reward bet on a single drug candidate, IMVT-1402.

• The Bull Case: If IMVT-1402 succeeds in its upcoming clinical trials, it could capture a massive market of over 4 million patients with strong patent protection lasting until at least 2043. The company also has a solid cash runway to fund operations into mid-2028.
• The Bear Case: With the failure of batoclimab, the company has no backup plan. Any setbacks in IMVT-1402's development, partner disputes, or manufacturing issues could severely impact the company's value. Additionally, minority investors have very limited voting power due to Roivant's majority control.

If you have a high risk tolerance and believe in the potential of IMVT-1402, Immunovant offers an intriguing opportunity. If you prefer companies with diversified pipelines or proven revenue streams, you may want to watch this one from the sidelines.